January 11th 2025
Through this global alliance, PackGene, Weill Cornell Medicine, and GC4K, an Australian non-profit, intend to deliver a custom-tailored gene therapy solution to treat hereditary spastic paraplegia type 56, a particularly rare neurological disease.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
HCATS, apceth Biopharma Form Strategic Manufacturing Agreements with bluebird bio
May 13th 2020Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma entered into long-term development and manufacturing services agreements for the clinical and commercial supply of multiple bluebird bio therapies.
Quartic.ai and Bright Path Labs Will Use AI for API Continuous Manufacturing
May 6th 2020Quartic.ai and Bright Path Laboratories have agreed to develop an artificial intelligence (AI)-powered continuous manufacturing platform for APIs and other small-molecule drugs using Bright Path Labs’ continuous bioreactor and the Quartic.ai smart manufacturing technology.